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Abstract
The storage polymer glycogen normally contains small amounts of covalently attached phosphate 
as phosphomonoesters at C2, C3 and C6 atoms of glucose residues. In the absence of the laforin 
phosphatase, as in the rare childhood epilepsy Lafora disease, the phosphorylation level is elevated 
and is associated with abnormal glycogen structure that contributes to the pathology. Laforin 
therefore likely functions in vivo as a glycogen phosphatase. The mechanism of glycogen 
phosphorylation is less well-understood. We have reported that glycogen synthase incorporates 
phosphate into glycogen via a rare side reaction in which glucose-phosphate rather than glucose is 
transferred to a growing polyglucose chain (Tagliabracci et al. (2011) Cell Metab 13, 274-282). 
We proposed a mechanism to account for phosphorylation at C2 and possibly at C3. Our results 
have since been challenged (Nitschke et al. (2013) Cell Metab 17, 756-767). Here we extend the 
evidence supporting our conclusion, validating the assay used for the detection of glycogen 
phosphorylation, measurement of the transfer of 32P from [β-32P]UDP-glucose to glycogen by 
glycogen synthase. The 32P associated with the glycogen fraction was stable to ethanol 
precipitation, SDS-PAGE and gel filtration on Sephadex G50. The 32P-signal was not affected by 
inclusion of excess unlabeled UDP before analysis or by treatment with a UDPase, arguing against 
the signal being due to contaminating [β-32P]UDP generated in the reaction. Furthermore, 
[32P]UDP did not bind non-covalently to glycogen. The 32P associated with glycogen was released 
by laforin treatment, suggesting that it was present as a phosphomonoester. The conclusion is that 
glycogen synthase can mediate the introduction of phosphate into glycogen, thereby providing a 
possible mechanism for C2, perhaps C3, phosphorylation.
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1. Introduction
Glycogen is a branched polymeric storage form of glucose present in many cell types. The 
polymerizing glucose residues are linked by α-1,4-glycosidic bonds formed by the action of 
glycogen synthase ([1]; Fig. 1). The branches are introduced as α-1,6-glycosidic linkages by 
the branching enzyme. Glycogen contains other minor constituents besides glucose, the most 
important of which is covalently attached phosphate [2-5]. Measurements of the abundance 
of the phosphate have ranged from ~1:500 to ~1:5000 phosphates per glucose residue and 
depend on the source of the glycogen. Recent studies suggest that the phosphate exists as 
monoesters at C2, C3 and C6 carbons of glucose residues within the glycogen [6, 7]. Plant 
amylopectin, which is a close relative of glycogen both chemically and functionally, also 
contains C3 and C6 phosphomonoesters of glucose [8-11]. No specific function for the 
phosphate in glycogen is known but its hyperaccumulation appears to disrupt normal 
glycogen structure [12]. The best evidence comes from studies of Lafora disease [13-17], a 
fatal teenage-onset myoclonic epilepsy in which an abnormal glycogen-like polymer forms 
insoluble deposits, Lafora bodies, in neurons, heart, skeletal muscle, skin and other tissues. 
Lafora disease has been linked, in about 90% of cases, to recessive mutations in one of two 
genes, EPM2A and EPM2B/NHLRC1, which encode respectively the proteins laforin [18, 
19] and malin [20]. Mice with either locus disrupted accumulate Lafora bodies and have a 
number of the neurological defects seen in the human disease [13-17, 21]. Laforin, which by 
sequence can be placed in the sub-family of atypical dual specificity protein phosphatases 
[22], has been shown to dephosphorylate amylopectin [23, 24], glycogen [24], and phospho-
oligosaccharides in vitro [25]. Furthermore, glycogen isolated from laforin or malin 
knockout mice has an elevated phosphate content [6, 24, 26] and, with aging, the glycogen 
becomes less branched and less water soluble, consistent with the formation of Lafora 
bodies [12]. Therefore, laforin appears to act as a glycogen phosphatase in vivo and its 
absence results in abnormal glycogen structure which may underlie the pathology of Lafora 
disease.
The origin of the phosphate present in glycogen is less well understood [5]. Nonetheless, the 
mechanism of glycogen phosphorylation is an important issue, not only for our fundamental 
understanding of glycogen metabolism but also because it could guide efforts to suppress 
glycogen phosphate accumulation as a therapy for Lafora disease. The phosphate present in 
plant starch is known to be introduced by specific dikinase enzymes [27-29]. However, 
neither bioinformatic nor biochemical studies have so far revealed comparable enzymes in 
mammals. Another possibility, that we have proposed, is that glycogen synthase itself can 
introduce covalently-linked phosphate into glycogen. By using [β-32P]UDP-glucose as a 
substrate, we had shown that glycogen synthase could incorporate 32P into newly 
synthesized glycogen. We attributed this result to the transfer of the β-phosphate of UDP-
glucose into glycogen as a rare side reaction, once every ~10,000 normal catalytic cycles 
([25]; Fig. 1). We proposed that the mechanism might involve a cyclic phosphate diester 
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intermediate that could explain phosphorylation at C2 and possibly at C3. It is difficult, 
however, to explain C6 phosphorylation by such a mechanism. Enzymological and structural 
studies did provide further support the involvement of cyclic phosphate [30]. First, a crystal 
structure of glycogen synthase with glucose-1,2-cyclic phosphate bound indicated that the 
catalytic site could accommodate the cyclic ester in a manner consistent with the proposed 
mechanism. Secondly, incubation of glycogen synthase with UDP-glucose resulted in the 
generation of the cyclic phosphate. Others have challenged this conclusion, suggesting that 
the 32P signal detected was due to the normal reaction product [β-32P]UDP binding non-
covalently to glycogen [7]. In the present study, we describe more extensive investigation of 
the phosphorylation of glycogen and provide further evidence that glycogen synthase is 
capable of transferring the β-phosphate of UDP-glucose to glycogen.
2. Materials and methods
2.1 Reagents
[γ-32P]ATP (NEG002A001MC; specific activity 3,000 Ci/mmol in 10 mM Tricine pH 7.6) 
and UDP-[U-14C]glucose (NEC403V050UC; specific activity 250 mCi/mmol in 
ethanol:water 2:98) were from PerkinElmer. UDP for competition assays was from Sigma 
(#94330). High purity UDP (99.2%) used in laforin reactions was from Chem-Impex 
International, Inc. (#00310). [α-32P]UDP (SCP230/37; specific activity 6,000 Ci/mmol in 50 
mM Tricine pH 7.4) was from Hartmann Analytic. Materials for gel filtration experiments 
were Sephadex G-50 (Sigma, G-50-150) and Spin Columns (Promega, C1281). Glycogen 
was purified from the skeletal muscle of New Zealand White rabbits as described previously 
[6].
2.2 Enzymes
Recombinant yeast Gsy2p was produced in E. coli and purified as described by Baskaran et 
al. [31]. Recombinant human GYS1 glycogen synthase was produced in insect cells and 
purified as described by Khanna et al. [32]. Hexokinase (#1012765501) and 
pyrophosphatase (#91078329) were from Roche. Phosphoglucomutase (#46550003) was 
from Oriental Yeast Co., LTD. Recombinant mouse laforin, wild type and C266S mutant, 
were purified as described previously [33]. Recombinant Leishmania UDP-glucose 
pyrophosphorylase protein was produced and purified as described by Lamerz et al. [34]. 
Recombinant human soluble calcium-activated nucleotidase (hSCAN-1) was produced and 
purified as previously described [35].
2.3 Synthesis of [β-32P]UDP-glucose
The synthesis of [β-32P]UDP-glucose was similar to the protocol described by Heyen et al 
[36]. 32P from the γ-phosphate of ATP is transferred to glucose by hexokinase, the resulting 
glucose-6-P isomerized by phosphoglucomutase to glucose-1-P which is converted to UDP-
glucose by UDP-glucose pyrophosphorylase. [γ-32P]ATP (~1.5 mCi at a specific activity of 
3,000 Ci/mol) was dried under nitrogen and then dissolved in 160 μl of a solution containing 
62.5 mM Tris-HCl pH 7.6, 6.25 mM glucose, 7.5 mM MgCl2, 1 mM UTP, 1.125 mM DTT, 
16 U/ml pyrophosphatase, 38 U/ml phosphoglucomutase and 13 μg/ml of Leishmania UDP-
glucose-pyrophosphorylase. The reaction was started by addition of 40 μl of hexokinase for 
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a final concentration of 30 U/ml in the 200 μl reaction volume. After incubation at 30°C for 
2 hr, the reaction was terminated by boiling in a water bath for 5 min followed by cooling on 
ice and centrifugation for 10 min at 15,000 x g at 4°C to remove denatured proteins.
We also developed a two-step procedure in which the hexokinase reaction was conducted 
separately and the ATP concentration was increased by addition of unlabeled nucleotide. 
[γ-32P]ATP (~1.5 or 3 mCi) was dried as above, dissolved in 80 μl of 62.5 mM Tris-HCl pH 
7.6, 6.25 mM glucose, 7.5 mM MgCl2, 31.25 μM ATP and the reaction initiated by addition 
of 20 μl of hexokinase for a final concentration of 30 U/ml. After incubation at 30°C for 60 
min, the reaction was terminated by boiling in a water bath for 5 min, cooled on ice and 
centrifuged for 10 min at 15,000 x g at 4°C. The supernatant was transferred to a new tube to 
which the remaining enzymes were added for final concentrations of 13 U/ml 
pyrophosphatase, 30 U/ml phosphoglucomutase and 13 μg/ml UDP-glucose 
pyrophosphorylase in a 200 μl reaction containing 50 mM Tris-HCl pH 7.6, 6 mM MgCl2, 
0.9 mM dithiothreitol (DTT), 0.8 mM UTP. After 60 min at 30°C, the reaction was 
terminated by boiling in a water bath for 5 min, cooled on ice, and centrifuged for 10 min at 
15,000 x g at 4°C to remove denatured proteins.
In either procedure, the [β-32P]UDP-glucose was purified by adsorption on activated 
charcoal. The supernatant was transferred to a tube containing ~7 mg charcoal, vortexed for 
1 min and incubated on ice for 10 min. The activated charcoal was collected by 
centrifugation at 15,000 x g for 2 min at 4°C. The charcoal was then suspended in 1 ml ice 
cold water (from MilliQ), vortexed for 30 sec, and centrifuged at 15,000 x g for 2 min at 
4°C. After three washes, [β-32P]UDP-glucose was eluted by suspending the charcoal in 200 
μl of 0.16 M NH4OH in 50% (v/v) ethanol, vortexing for 30 sec and centrifuging at 15,000 x 
g for 2 min at 4°C, for a total of 4 elutions. The pooled eluates were centrifuged once more 
and the supernatant passed through a Costar Spin-X Centrifuge Tube Filter that had been 
equilibrated in 0.16 M NH4OH, 50% (v/v) ethanol to remove any residual charcoal. The 
filtered eluate was dried extensively in a Speed Vac, dissolved in 100 μl of 10 mM Tris-HCl 
pH 7.5 and stored in aliquots at −80°C.
The radiochemical purity of the [β-32P]UDP-glucose was assessed by TLC as in Heyen et al. 
[36] and judged to be ~99% pure. All radioactivity was converted to glucose-1-32P by 
treatment with UDP-glucose pyrophosphatase [36]. Both synthetic protocols yielded 
[β-32P]UDP-glucose of similar purity but the two-step procedure had higher yields, ~70% of 
the starting radioactivity compared to the one-step method, ~50%. [β-32P]UDP-glucose 
purified by the two step method was used for most of the experiments reported.
2.4 Preparation and SDS-PAGE analysis of 32P and 14C glycogen
Purified rabbit skeletal muscle glycogen was incubated with recombinant yeast or human 
glycogen synthase enzymes essentially as described by Tagliabracci et al. [25] to 
produce 14C- or 32P-labeled glycogen1. Glycogen synthase was diluted into 50 mM Tris-
1For simplicity we sometimes refer to the polymer synthesized in vitro by incubation of glycogen and glycogen synthase as 
“glycogen” although technically this is not strictly correct since the elongated outer chains will not have the branching pattern of 
native glycogen.
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HCl pH 7.8, 1 mg/ml glycogen,1mM DTT immediately prior to being added to start the 
reactions. The glycogen synthase reactions contained 50 mM Tris HCl pH7.8, 5 mM EDTA, 
7.2 mM glucose-6-P, 6.9 mg/ml glycogen, 2-5 μM UDP-[U-14C]-glucose (330-450 cpm/
pmol) or [β 32P]-UDP-glucose (75,000-260,000 cpm/pmol), and yeast (2-10 μg/ml) or 
human (20 μg/ml) glycogen synthase. Control reactions lacked glycogen synthase. At the 
indicated times, samples were removed, boiled in a water bath for 5 min, cooled on ice, and 
centrifuged to collect the reaction solution. In some cases, small aliquots were withdrawn for 
analysis by TLC. Glycogen was precipitated from the remainder by addition of 2 volumes of 
cold (−20°C or −80°C) 100% ethanol, as well as Na2SO4 and LiCl to final concentrations of 
2.8 mM and 20 mM respectively to aid precipitation. Samples remained at −20°C for a 
minimum of 4 hr to allow precipitation, boiled for 2 min to aid glycogen aggregation, cooled 
on ice for 10 min, centrifuged at 15,000 x g for 30 min and the supernatant removed. The 
pellet was dried with a Speed Vac and then dissolved in water or buffer as needed, usually to 
the original sample volume. If further precipitations were to be performed, LiCl was added 
to a concentration of 2 mM followed by 2 volumes of cold ethanol and processed as 
described above. For SDS-PAGE, glycogen pellets were dissolved in 25 μl of water or buffer 
and 1/5 volume of 5X SDS loading buffer (60 mM Tris-PO4 pH 6.8, 40% glycerol, 5% SDS, 
0.08% Bromophenol Blue, and 5%(v/v) β-mercaptoethanol), boiled for 5 min and samples 
were loaded into wells on a 10% (w/v) acrylamide gel with a 4% (w/v) stacking gel. 
Loadings corresponded to 250-375 μg of the initial glycogen present in the reaction. Gels 
were developed with 180 volts for ~45 min. After electrophoresis, gels were dried and 
imaged with a FujiFilm FLA-5100 Phosphorimager.
2.5 Treatments of 32P- and 14C-labeled glycogen
32P- and 14C-labeled glycogen produced by glycogen synthase reactions was purified 
through ethanol precipitation(s) and subjected to various additional treatments prior to 
analysis by SDS-PAGE.
Gel filtration—After reaction with glycogen synthase, the glycogen underwent two rounds 
of ethanol precipitation, as described above except that the reaction was diluted two-fold 
initially and dissolved in two times the reaction volume after the first precipitation. The 
glycogen was finally dissolved in 150-160 μl of 10 mM Tris-HCl pH 7.5. A portion (70 μl) 
was subjected to gel filtration on a spin column (Promega) containing ~1 ml of packed 
Sephadex G50 resin (Sigma) which had been equilibrated with 10 mM Tris-HCl pH 7.5 and 
extensively washed with the same buffer. Immediately prior to loading the samples, excess 
buffer was removed by centrifugation (1,000 x g for 1 min at 16°C). Sample (70 μl) was 
applied to the spin column, the column centrifuged (1,000 x g for 1 min at 16°C), and the 
flow-through collected. The gel filtered glycogen and an equivalent unfiltered aliquot of 70 
μl were dried in a Speed Vac, dissolved in 25 μl of 10 mM Tris-HCl pH 7.5 and aliquots (20 
μl) were made 1X in SDS loading buffer and subjected to SDS-PAGE. From quantitation of 
the 14C-labeled glycogen, recovery after gel filtration was ~95%.
Glucosidase and laforin treatment—After ethanol precipitation, glycogen was 
dissolved in water and adjusted to 20 mM sodium acetate, pH 4.8. For glucosidase 
treatment, the glycogen was incubated with or without 0.3 mg/ml of both α-amylase and 
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amyloglucosidase, unless noted otherwise, for 2 hr at 42°C. In other experiments, the 
glycogen was incubated with 25 or 50 μg/ml of either mouse wild type laforin or 
catalytically inactive C266S laforin at 37°C for 2 hr. Samples were boiled for 5 min, cooled 
on ice, and condensation collected by centrifugation prior to analysis by SDS-PAGE. For 
analysis of 32Pi release, 32P-glycogen was purified by ethanol precipitation, treatment with 
PiBind™ resin (Innova Biosciences, 501-0051) and gel filtration as described above. The 
PiBind™ resin binds and removes free inorganic phosphate from samples and is marketed 
for this purpose. This step was added to minimize inorganic phosphate contamination of 
the 32P-glycogen. We observed that the resin also chelated and removed UDP and UDP-
glucose, but not 32P-glycogen, from our samples (data not shown).
Hydrolysis of UDP with recombinant human soluble calcium-activated 
nucleotidase (hSCAN-1)—hSCAN-1 is a nucleotidase that converts UDP to UMP but 
cannot hydrolyze UMP [35, 37] or UDP-glucose and glucose-6-P (data not shown). 32P- 
and 14C-labeled glycogen produced by glycogen synthase action was purified by three 
cycles of ethanol precipitation, dissolved in 50 mM Tris-HCl pH 7.5, 0.05% (v/v) Tween-20, 
and incubated at 37°C for 30 min with or without 1.2 μg/ml hSCAN-1 plus 2 mM CaCl2. 
Reactions were terminated by boiling and processed for SDS-PAGE as described. In other 
experiments, glycogen synthase reactions were terminated by boiling, 2 mM UDP was 
added and the sample incubated at 37°C for 30 min with or without 1.2 μg/ml hSCAN-1 
plus 2 mM CaCl2 in excess of the EDTA concentration. Samples were then analyzed by 
TLC and/or SDS-PAGE.
Competition with unlabeled UDP—32P- and 14C-labeled glycogen produced by 
glycogen synthase action was purified by three cycles of ethanol precipitation and dissolved 
in 50 mM Tris-HCl pH 7.5, 0.05% (v/v) Tween-20. Once the glycogen was completely in 
solution, 2 mM UDP was added, so as to be at a 1000-fold excess compared to labeled UDP-
glucose, and incubated at room temperature for 30 min. In other experiments, the UDP was 
added prior to ethanol precipitation. Samples were then processed and analyzed by SDS-
PAGE.
2.6 Thin Layer Chromatography
Two chromatographic systems were used. High-performance thin layer chromatography 
(HPTLC) plates (Merk, Silica gel 60 F254) were used for TLC analysis of nucleotides when 
reaction mixes were treated with hSCAN-1. One or two μl of sample was spotted on the 
plate which was developed by ascending chromatography with n-propanol:ethyl 
acetate:water (7:1:4). Plates were laid flat and allowed to air dry at room temperature. 
Radioactivity was visualized using either a Phoshorimager or by exposing the plates to X-
ray film. For visualization of UV absorbing compounds, the plates were placed under a UV 
lamp (λ = 254 nm), the UV absorbing regions were marked, and a photograph of the plate 
was taken. For analysis of 32Pi release from 32P-glycogen, polyethyleneimine (PEI) cellulose 
plates (Merck, 1.05725.0001) were developed by ascending chromatography with 1M acetic 
acid: 3M LiCl (9:1). Plates were air dried and imaged as described above.
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2.7 Analysis of laforin activity towards UDP and UDP-glucose
The ability of laforin to hydrolyze UDP was tested by incubating 2.5 mM UDP with 25 
μg/ml wild type laforin in 20 mM sodium acetate, pH 4.8 for 2 hr at 37°C. A control 
reaction contained 25 μg/ml catalytically inactive C266S laforin. UDP-glucose, 2.5 mM, was 
also tested as a substrate. The wild type laforin hydrolyzed p-nitrophenolphosphate (specific 
activity 5.3 nmol/min/μg). The reactions were incubated at 37°C for 2 hr and terminated by 
boiling for 5 min. Samples, diluted to 50 μM with respect to the starting UDP or UDP-
glucose concentrations, were passed through a centrifuge filter (Costar Spin-X, 8160) and 25 
μl aliquots loaded onto a PA200 column for separation by high-performance anion exchange 
chromatography (HPAEC) using a Dionex ICS 3000 instrument and a gradient of sodium 
acetate. The starting mobile phase, eluent A, consisted of 1 mM NaOH and eluent B was 1 
mM NaOH, 1M sodium acetate. The elution profile, in terms of percentage of eluant B, was 
20-50% from 0-10 min, 55-85% from 10-35 min and 85-100% from 35-40 min with a flow 
rate of 0.30 ml/min. The nucleotides were detected by UV absorption at 262 nm.
2.8 Assessment of UDP binding to glycogen
Rabbit skeletal muscle glycogen at 8.3 mg/ml was incubated in 50 mM Tris-HCl pH 7.8, 5 
mM EDTA, 7.2 mM glucose-6-P, 1 μM UDP-[U-14C]glucose (specific activity ~450 cpm/
pmol), with or without 4 μM [α-32P]UDP(specific activity of ~100,000 cpm/pmol), and with 
or without 10 μg/ml yeast glycogen synthase for 60 min at 30°C. The incubation was 
initiated by addition of glycogen synthase or vehicle. Reactions were terminated by boiling 
for 5 min, cooled on ice, and precipitated with ethanol as already described. After drying in 
a Speed Vac, glycogen was dissolved in 1) 48 μl of water, 2) 5 mM UDP or 3) 20 mM 
sodium acetate pH 4.8 for glucosidase digestion. Amyloglucosidase and α-amylase, each at 
60 μg/ml, were added and incubated overnight at 40°C. Control samples were kept at −20°C. 
All samples were boiled for 5 min, cooled on ice and analyzed by SDS-PAGE.
3. Results and discussion
3.1 Assay of the incorporation of the β-phosphate of UDP-glucose into glycogen
The assay for glycogen phosphorylation by glycogen synthase is based on a procedure 
developed for measurement of glucose-1-phosphotransferase activity involved in 
glycoprotein synthesis [38]. Central to the method is the use of [β-32P]UDP-glucose as a 
substrate so that if the β-phosphate is transferred, 32P-glycogen is formed by elongating 
unlabeled glycogen (Fig. 1, lower reaction). With this substrate, the normal transfer of 
glucose to glycogen is accompanied by the generation of [β-32P]UDP as product. Separation 
of [β-32P]UDP from glycogen after the reaction is achieved by 1) precipitation of glycogen 
with ethanol followed by re-dissolving in aqueous solution (one to three times) and 2) SDS-
PAGE. By incubating with either UDP-[U-14C]glucose or [β-32P]UDP-glucose, time-
dependent increases in both 14C and 32P signals were observed, using purified yeast 
glycogen synthase, as we reported previously (Fig. 2; [25]). High molecular weight 
glycogen is mostly retained at the bottom of the well, although signal often extends into the 
stacking gel, presumably smaller polysaccharide molecules that sometimes accumulate at 
the stacking-separating gel interface (just visible in Fig. 2, more prominent in some other 
figures). Negatively charged, small molecules like nucleotides would be expected to migrate 
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through the separating gel where no radioactivity was detected (Fig. 2). Note that even in 
control reactions lacking enzyme a detectable background at the bottom of the well is always 
observed when [β-32P]UDP-glucose is used but less so with UDP-[U-14C]glucose.
3.2 Evidence that phosphate incorporated by glycogen synthase is associated with 
glycogen
Gel filtration is frequently used as a means to remove small, non-covalently bound ligands 
from macromolecules. Therefore, we applied this technique to analyze glycogen elongated 
by incubation with [β-32P]UDP-glucose and glycogen synthase to see whether the 
radioactive signal attributed to 32P-glycogen could be eliminated or reduced by gel filtration. 
Parallel reactions contained UDP-[U-14C]glucose. After the ethanol precipitation of 
glycogen, one aliquot of the re-dissolved samples was additionally subjected to gel filtration 
through Sephadex G50 prior to SDS-PAGE. Reactions with purified yeast (Fig. 3A) or 
human (Fig. 3B) glycogen synthase gave the expected time-dependent increase in both 32P 
and 14C labeling. Gel filtration, in our hands, had little effect on these signals when 
compared to samples that had not passed through Sephadex G50 (Fig. 3). Note that in 
controls (lanes “C”), incubations with [β-32P]UDP-glucose present but lacking glycogen 
synthase, background was still detected even after gel filtration. However, we conclude that 
the bulk of the 32P or 14C radioactivity running with glycogen in SDS-PAGE is stable to gel 
filtration.
Evidence that the 32P is covalently linked to the synthesized polysaccharide comes from the 
fact that catalytically active wild-type laforin, which has well documented glucan 
phosphatase activity, was able to reduce the 32P-signal to the background level (Fig. 4A). 
Laforin had no effect on the 14C-signal. In a control, the glycogen was exposed to a 
catalytically inactive C266S laforin mutant protein, unable to dephosphorylate glycogen 
[24], which caused no change in either the 32P or the 14C signal. As expected, treatment of 
the elongated glycogen with glucosidases (amyloglucosidase and α-amylase) to degrade the 
glucose polymer eliminated both the 32P and the 14C signals, implying their association with 
the synthesized glycogen, as has been previously shown.
The argument could be made that laforin removes the β-phosphate of [β-32P]UDP non-
covalently bound to glycogen. Although there have been no reports of such an activity for 
laforin, we tested this hypothesis by incubating active or C266S mutant laforin with UDP 
and analyzing the nucleotide composition by HPAEC. Even commercially available UDP of 
the highest purity (99.2%) had trace amounts of contaminating UMP by this analysis (Fig. 
4B). However, exposure of the UDP to either wild-type or C266S mutant laforin had no 
effect on the UDP level and no increase in UMP was detected. Nor was UDP-glucose a 
substrate for hydrolysis by laforin (Fig. 4B), as expected for a monoesterase. The simplest 
conclusion from these experiments is that laforin hydrolyzes phosphomonesters present in 
the glycogen.
In other experiments, we showed that exposure of 32P-glycogen to laforin led to the release 
of 32P-labeled inorganic phosphate (32Pi) (Fig. 5A). The 32P-glycogen in this case was 
purified by ethanol precipitation, gel filtration and treatment with PiBind™ resin to eliminate 
phosphate contamination. The reaction products were analyzed by TLC using PEI-cellulose 
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plates. Labeled glycogen was concentrated at the origin with a “comet trail” extending into 
the chromatogram (Fig 5). The presence of active laforin resulted in the generation of 32Pi 
and a reduction in the 32P-glycogen signal (Fig. 5A) whereas the 14C-glycogen signal was 
unchanged (Fig. 5B). When laforin was omitted (“C”) or heat inactivated (“HI”), no 
phosphate signal was visible. We conclude that the 32P is covalently attached to glucose 
residues of glycogen by phosphomonoester linkages and that laforin can release inorganic 
phosphate from glycogen by hydrolysis.
3.3 Further controls that [32P]UDP binding to glycogen is not responsible for the 
radioactivity associated with 32P-glycogen
To address the possibility that the 32P signal associated with the synthesized glycogen is 
caused by non-covalent binding of the [β-32P]UDP produced in the reaction, we conducted 
three other types of control experiments. In the first, we added a 1000-fold molar excess of 
unlabeled UDP after the glycogen synthesis reactions but before analysis by SDS-PAGE 
(Fig. 6). Were the 32P associated with glycogen due to the presence of [β-32P]UDP, the 
unlabeled UDP should be able to compete with the radioactive nucleotide. However, no 
effect of cold UDP on the 32P-glycogen signal was detected, whether added before (data not 
shown) or after the ethanol precipitation step (Fig. 6). As expected, the presence of 
unlabeled UDP had no effect on the 14C-signal in the control reaction.
In a second approach, advantage was taken of hSCAN-1, a UDPase that hydrolyzes UDP to 
UMP [35, 37] but which does not hydrolyze UDP-glucose or UMP. In Fig. 7, glycogen 
synthase reactions were analyzed, using either [β-32P]UDP-glucose or UDP-[U-14C]glucose 
as substrate, with aliquots withdrawn at the indicated times, the reaction terminated by 
boiling for 5 min, exposed or not to hSCAN-1, separated by TLC and visualized under UV 
light and also quantitated with a Phosphorimager. During the glycogen synthase reaction, we 
observed a time dependent consumption of the radioactive UDP-glucose substrate; with 
[β-32P]UDP-glucose, the concomitant generation of [β-32P]UDP was detected and with 
UDP-[U-14C]glucose there was sufficient signal to observe 14C-glycogen accumulation at 
the origin of the plate. Small amounts of glucose-1,2-cyclic phosphate, the fast ester of 
Leloir [39], were also detected; it is a normal contaminant of UDP-glucose. The presence of 
hSCAN-1 correlated with the detection of inorganic 32Pi whose accumulation matched the 
disappearance of [β-32P]UDP-glucose. The amount of radioactive UDP-glucose was low 
enough (2 μM) that it was not detectable by UV on the TLC plate. Therefore, additional 
UDP was added before exposure to hSCAN-1. The essentially complete conversion of UDP 
to UMP by hSCAN-1 was evident by monitoring the UV absorbance on the TLC plate. 
Having established that hSCAN-1 could convert [β-32P]UDP to 32Pi and unlabeled UMP 
under relevant conditions, we went on to conduct glycogen synthetic reactions with 
[β-32P]UDP-glucose or UDP-[U-14C]glucose as substrates and exposed the products to 
hSCAN-1 after (Fig. 8) or prior to (not shown) ethanol precipitation followed by analysis by 
SDS-PAGE (Fig. 8). Exposure to hSCAN-1 did not decrease the incorporation of either 32P 
or 14C into glycogen with either protocol, providing further evidence that the observed 32P 
signal was not due to [β-32P]UDP.
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A third control was to test whether non-covalent association of 32P-UDP with glycogen 
could be detected after SDS-PAGE. For these experiments, we utilized commercially 
available [α-32P]UDP. The amount of [α-32P]UDP radioactivity present (550,000 cpm/μl) 
exceeded the amount of radioactivity in [β-32P]UDP-glucose (180,000-400,000 cpm/μl) used 
in the glycogen labeling experiments described above. UDP-[U-14C]glucose was present at 
400-1,800 cpm/μl. After incubation with glycogen, the presence of [α-32P]UDP contributed 
a slight increase in background corresponding to the region where glycogen runs at the 
bottom of the gel well when compared with reactions containing only UDP-[U-14C]glucose 
(Figs. 9A and B, comparing lanes 4 and 8). A signal with a diffuse appearance was also seen 
above the stacking-separating gel interface, which was not observed in reactions lacking 
[β-32P]UDP. The presence of a 1,000-fold molar excess of unlabeled UDP had no effect on 
either signal (Fig. 9B, lanes 5 and 9) and neither did treatment with glucosidases (Fig. 9A, 
compare lanes 5 and 9 to lanes 4 and 8, respectively). This background radioactivity is 
therefore associated with neither glycogen nor UDP. To mimic better the glycogen synthesis 
reactions with [β-32P]UDP-glucose, in which [β-32P]UDP is generated concomitant with 
chain elongation that might physically trap the UDP, parallel incubations were conducted in 
the presence of glycogen synthase. The glycogen synthase was active as indicated by the 
generation of a radioactive signal, due to 14C incorporation, at the well bottoms (Figs. 9A 
and B, lane 6). In the presence of [α-32P]UDP, there was no increase in the radioactive 
signal (Figs. 9A and B, compare lanes 2 and 6). The presence of cold UDP had no effect 
(Fig. 9A, compare lanes 3 and 7 to lanes 2 and 6, respectively) whereas treatment with 
glucosidases returned the signals to background (Fig. 9B, lanes 3 and 7). We therefore found 
no evidence under our conditions for non-covalent binding of 32P-UDP to glycogen 
sufficient to account for the 32P incorporation into glycogen observed when [β-32P]UDP-
glucose was incubated with glycogen synthase.
4. Conclusion
All enzyme assays that utilize a radioactive substrate to monitor the progress of a chemical 
reaction depend on the ability to physically separate product from substrate. The most 
common standard assay for glycogen synthase activity, as an example, monitors the transfer 
of [U-14C]glucose from UDP-[U-14C]glucose into glycogen, taking advantage of the 
insolubility of glycogen in ethanol to separate substrate and product [40]. Reaction aliquots 
are typically deposited on filter paper squares, immersed in 66% (v/v) ethanol, and washed 
extensively before quantitating the ethanol-insoluble radioactivity. In the present study, it is a 
minor side reaction that is of interest, [32P]phosphate incorporation into glycogen, and so the 
task is to resolve 32P-glycogen from unreacted [β-32P]UDP-glucose as well as the main 
radioactive reaction product, [β-32P]UDP. Furthermore, since the side reaction occurs at a 
rate about one ten thousandth of the rate of the main reaction, very high specific activity 
[β-32P]UDP-glucose (75,000-260,000 cpm/pmol) is necessary to obtain sufficient sensitivity. 
This requires that even the most minor radioactive impurities must be considered. We found 
early in our studies that the standard filter paper assay was inadequate for monitoring 32P 
incorporation into glycogen because of very high backgrounds. We therefore developed a 
protocol in which glycogen synthesis reactions were terminated, the polysaccharide was first 
separated from the bulk reactants by ethanol precipitation, the precipitate re-dissolved in 
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SDS-buffer, boiled and then subjected to SDS-PAGE [25]. The rationale was that non-
covalent interactions would not survive this treatment. Indeed, SDS-PAGE is frequently and 
successfully used to separate 32P-labeled proteins from high specific activity [γ-32P]ATP in 
protein kinase reactions validating in principle the concept that radioactive nucleotides can 
be removed by gel electrophoresis. From the experiments described in this work, we have 
confirmed our previous findings and added several additional controls that further validate 
the analysis. The 32P-signal that we attribute to 32P-glycogen is stable to gel filtration, 
unaffected by inclusion of molar excesses of cold UDP, unaffected by exposure to a specific 
UDPase and susceptible to laforin treatment. In addition, we find no evidence for significant 
non-covalent binding of UDP to glycogen.
Since our first report that glycogen synthase could transfer phosphate to glycogen [25], 
Nitschke et al [7] concluded that the 32P-signal, which we had interpreted to be 32P-labeled 
glycogen, was in fact caused by contaminating [β-32P]UDP bound tightly enough to 
glycogen to remain associated with the polymer through the SDS-PAGE separation. Their 
most compelling evidence was that gel filtration of samples significantly reduced the 32P-
signal seen after SDS-PAGE, although it was not entirely eliminated and a weaker signal 
remained that increased with reaction time. In this present study, we cannot corroborate their 
findings and show instead that the main 32P-signal that we have studied is stable to gel 
filtration. The other principal difference between our results and those of Nitschke et al [7] 
concerns the susceptibility of synthesized 32P-glycogen to hydrolysis by laforin. In our 
hands, we are able to reduce the 32P signal of the glycogen to background level by exposure 
of the glycogen to active laforin. In addition, exposure of 32P-glycogen to active laforin 
generated free 32Pi. These results we take as evidence that the 32P is covalently attached to 
glycogen by a phosphomonoester bond, given the known substrate specificity of laforin. 
Thus, from the multiple lines of evidence presented in this study, we are confident that the 
large majority of the 32P-signal associated with glycogen is indeed due to covalent 
phosphorylation of the polysaccharide by glycogen synthase.
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Highlights
• Glycogen synthase incorporates β-phosphate of UDP-glucose into glycogen
•
32P-labeling of glycogen using [β-32P]UDP-glucose as substrate monitors the 
reaction
• The 32P associated with glycogen is not due to the non-covalent binding of 
[β-32P]UDP
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Figure 1. 
Reactions of glycogen synthase. Shown are (a) the primary reaction catalyzed by glycogen 
synthase in which glucose is transferred from the substrate UDP-glucose to the non-reducing 
end of a polyglucose chain in glycogen and (b) the side reaction in which the β-phosphate of 
UDP-glucose is transferred to add a glucose-phosphate unit (see text). The rate constants are 
to indicate that the side reaction occurs at around one ten thousandth of the rate of the main 
reaction.
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Figure 2. 
Time-dependent incorporation of 32P into synthesized glycogen by glycogen synthase. 
Glycogen synthase (yeast Gsy2p, 5 μg/ml) was incubated with glycogen, and 2 μM 
[β-32P]UDP-glucose or UDP-[U-14C]glucose, aliquots were removed at the indicated times, 
precipitated with ethanol and analyzed by SDS-PAGE (see Materials and Methods). C 
indicates a control reaction lacking enzyme. Dried gels were analyzed by a Phosphorimager. 
The bottom of the gel wells and the stacking/separating gel interfaces are indicated with 
arrows.
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Figure 3. 
Effect of gel filtration on 32P-labeled glycogen. Reactions with 2 μM [β-32P]UDP-glucose 
(right panels) or [U-14C]glucose (left panels), glycogen and yeast (A) or human (B) 
glycogen synthase (2 μg/ml) were sampled at the indicated times, aliquots precipitated with 
ethanol two times, and treated or not by gel filtration over Sephadex G50 and analyzed by 
SDS-PAGE (see Materials and Methods). “C” indicates a control reaction lacking glycogen 
synthase. Dried gels were analyzed by a Phosphorimager.
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Figure 4. 
Effect of treating 32P-labeled glycogen with laforin or glucosidases. A Glycogen was labeled 
by incubation with 5 μM [β-32P]UDP-glucose (lower panel) or [U-14C]glucose (upper panel) 
and yeast glycogen synthase (2 μg/ml) for 30 min. Glycogen was precipitated with ethanol, 
dissolved in buffer and treated with α-glucosidases (α-amylase and amyloglucosidase) (α-
G), inactive mutant laforin (C266S Laf) or wild type laforin (WT Laf) as indicated, and 
analyzed by SDS-Page (see Materials and Methods). Dried gels were analyzed by a 
Phosphorimager. C, control reaction lacking glycogen synthase; NT, not treated. B UDP-
glucose and UDP were incubated with active (WT) or inactive (C266S) laforin as indicated 
and analyzed by HPAEC. Chromatograms of UDP, UMP and UDP-glucose standards are 
shown in the lowermost panel.
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Figure 5. 
Release of 32Pi from 32P-glycogen by laforin. Glycogen was labeled by incubation with 5 
μM [β-32P]UDP-glucose (A) or [U-14C]glucose (B) and yeast glycogen synthase (5 μg/ml) 
for 30 min. Glycogen was precipitated three times with ethanol, treated with PiBind™ resin, 
purified by gel filtration and dissolved in buffer. The glycogen was incubated for 2 hr with 
50 μg/ml laforin (WT Laf) or laforin inactivated by boiling for 5 min (HI Laf). A control (C) 
lacked laforin. The reaction mixtures were analyzed by TLC using PEI-cellulose plates. 
Standards of glucose-1-P (14C-G1P), glucose (14C-Glu) and inorganic phosphate (32Pi), 
labeled with the indicated isotope, were also analyzed.
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Figure 6. 
Effect of unlabeled UDP on 32P-labeling of glycogen. Glycogen was labeled by incubation 
with 2 μM [β-32P]UDP-glucose (lower panel) or [U-14C]glucose (upper panel) and yeast 
glycogen synthase (5 μg/ml) for the indicated times. Unlabeled UDP (2 mM, a 1000-fold 
excess of UDP-glucose) was added prior to SDS-PAGE (see Materials and Methods). C, 
control reaction lacking glycogen synthase.
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Figure 7. 
Analysis of the progress of glycogen synthesis by glycogen synthase. Glycogen was 
synthesized by incubation with 2 μM [β-32P]UDP-glucose (A,B) or [U-14C]glucose (C,D) 
and yeast glycogen synthase (5 μg/ml), and aliquots removed at the indicated times. C 
corresponds to reactions lacking glycogen synthase. After addition of 2 mM UDP, the 
aliquots were analyzed by TLC and visualized either by Phosphorimager (A,C) or UV (B, 
D). Standards of UDP-glucose, UMP, UDP and [32P]phosphate were present in the left most 
tracks and their migrations indicated. Prior to chromatography, the aliquots were treated or 
not with the UDPase hSCAN-1 for 30 min, as indicated (see Materials and Methods).
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Figure 8. 
Effect of hSCAN-1 treatment on 32P-labeling of glycogen. Glycogen was labeled by 
incubation with 2 μM [U-14C]glucose (upper panel) or [β-32P]UDP-glucose (lower panel) 
and yeast glycogen synthase (5 μg/ml), and aliquots removed at the indicated times. After 
ethanol precipitation, samples were treated with hSCAN-1(+hSCAN-1) or without 
(−hSCAN-1) for 30 min prior to analysis by SDS-PAGE (see Materials and Methods). C 
corresponds to reactions lacking glycogen synthase.
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Figure 9. 
Test for 32P-UDP binding to glycogen. Glycogen was incubated with [α-32P]UDP either 
with (lanes 2 and 3) or without (lanes 4 and 5) glycogen synthesis by 10 μg/ml glycogen 
synthase (GS) for 30 min. Samples were analyzed by SDS-PAGE and dried gels visualized 
with a Phosphorimager (see Materials and Methods). Controls lacked [α-32P]UDP (lanes 
6-9). In A, samples were treated or not with α-amylase and amyloglucosidase (α-G) and in 
B, unlabeled UDP (4 mM, a 1,000-fold excess over [α-32P]UDP) was added to some 
samples prior to SDS-PAGE.
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